PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19617399-7	2010	These findings suggest that novel therapies to activate AMPK in the CF airway may be beneficial by blunting excessive sodium and ASL absorption and by reducing excessive airway inflammation, which are major contributors to CF lung disease.	acetylsalicylic acid lysinate	129-132	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	56-60
21933594-8	2011	RESULTS: Compared to the PQ group rats, early treatment with LAS reduced the MDA and HYP contents, and increased the SOD, GSH-Px, and CAT activities in the serum and lung on days 1, 3, 7, 14, and 21 after PQ poisoning (all P < 0.05).	acetylsalicylic acid lysinate	61-64	glutathione peroxidase 1	Rattus norvegicus	122-128
21933594-8	2011	RESULTS: Compared to the PQ group rats, early treatment with LAS reduced the MDA and HYP contents, and increased the SOD, GSH-Px, and CAT activities in the serum and lung on days 1, 3, 7, 14, and 21 after PQ poisoning (all P < 0.05).	acetylsalicylic acid lysinate	61-64	catalase	Rattus norvegicus	134-137
21933594-9	2011	After early LAS treatment, the apoptotic rate and Bax expression of lung decreased, the Bcl-2 expression increased, and the Bcl-2/Bax ratio increased, compared to the PQ group rats.	acetylsalicylic acid lysinate	12-15	BCL2 associated X, apoptosis regulator	Rattus norvegicus	50-53
21933594-9	2011	After early LAS treatment, the apoptotic rate and Bax expression of lung decreased, the Bcl-2 expression increased, and the Bcl-2/Bax ratio increased, compared to the PQ group rats.	acetylsalicylic acid lysinate	12-15	BCL2, apoptosis regulator	Rattus norvegicus	88-93
21933594-9	2011	After early LAS treatment, the apoptotic rate and Bax expression of lung decreased, the Bcl-2 expression increased, and the Bcl-2/Bax ratio increased, compared to the PQ group rats.	acetylsalicylic acid lysinate	12-15	BCL2, apoptosis regulator	Rattus norvegicus	124-129
21933594-9	2011	After early LAS treatment, the apoptotic rate and Bax expression of lung decreased, the Bcl-2 expression increased, and the Bcl-2/Bax ratio increased, compared to the PQ group rats.	acetylsalicylic acid lysinate	12-15	BCL2 associated X, apoptosis regulator	Rattus norvegicus	130-133
19364771-4	2009	In well differentiated human airway epithelial cells, ASL [K(+)] was 20.8 +/- 0.3 mm and decreased by inhibition of the Na(+)/K(+) pump (ouabain), ENaC (amiloride), CF transmembrane conductance regulator (CFTR(inh)-172), or K(+) channels (TEA or XE991).	acetylsalicylic acid lysinate	54-57	CF transmembrane conductance regulator	Homo sapiens	205-209
18038616-1	2006	Intraperitoneal injections of lysine acetylsalicylate (L-ASA, aspirin) in a dose of 10 mg during 5 consecutive days to BALB/c and B10.PL mice increased the concentration of endogenous hydrogen sulfide in their livers.	acetylsalicylic acid lysinate	30-53	granzyme C	Mus musculus	130-133
19226274-7	2009	However, L-asa nasal challenge induced significantly increased levels of CCL5 in the sensitive patients but not in the tolerant subjects (median: 380 vs. 140 pg/mL, P<0.0001).	acetylsalicylic acid lysinate	9-14	C-C motif chemokine ligand 5	Homo sapiens	73-77
16421012-0	2006	Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers.	acetylsalicylic acid lysinate	53-76	integrin subunit alpha 2b	Homo sapiens	146-151
18038616-1	2006	Intraperitoneal injections of lysine acetylsalicylate (L-ASA, aspirin) in a dose of 10 mg during 5 consecutive days to BALB/c and B10.PL mice increased the concentration of endogenous hydrogen sulfide in their livers.	acetylsalicylic acid lysinate	55-60	granzyme C	Mus musculus	130-133
15464057-4	2004	Indomethacin or lysine-acetylsalicylic acid concentration-dependently inhibited prostaglandin E(2) biosynthesis and, at concentrations causing near-complete inhibition, enhanced TNFalpha mRNA and protein expression without significantly influencing cyclooxygenase-2 mRNA.	acetylsalicylic acid lysinate	16-43	tumor necrosis factor	Homo sapiens	178-186
15464057-4	2004	Indomethacin or lysine-acetylsalicylic acid concentration-dependently inhibited prostaglandin E(2) biosynthesis and, at concentrations causing near-complete inhibition, enhanced TNFalpha mRNA and protein expression without significantly influencing cyclooxygenase-2 mRNA.	acetylsalicylic acid lysinate	16-43	prostaglandin-endoperoxide synthase 2	Homo sapiens	249-265
15464057-5	2004	In addition, by facilitating endotoxin-induced TNFalpha expression, indomethacin or lysine-acetylsalicylic acid counteracted dexamethasone-induced inhibition of TNFalpha biosynthesis, thereby exhibiting an effect opposite to that of exogenous prostaglandin E(2).	acetylsalicylic acid lysinate	84-111	tumor necrosis factor	Homo sapiens	47-55
15464057-5	2004	In addition, by facilitating endotoxin-induced TNFalpha expression, indomethacin or lysine-acetylsalicylic acid counteracted dexamethasone-induced inhibition of TNFalpha biosynthesis, thereby exhibiting an effect opposite to that of exogenous prostaglandin E(2).	acetylsalicylic acid lysinate	84-111	tumor necrosis factor	Homo sapiens	161-169
10860637-4	2000	The relaxing effect of A II was also mediated through the release of cyclo-oxygenase products of arachidonic acid, as evidenced by the inhibition of the response by lysine acetylsalicylic acid (ASA) pretreatment.	acetylsalicylic acid lysinate	165-192	arginase type II	Mus musculus	23-27
15154853-0	2004	Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan.	acetylsalicylic acid lysinate	114-137	nitric oxide synthase 1	Rattus norvegicus	22-26
11413842-12	2001	LAS also showed better analgesic efficacy than PAR as assessed by measures of PID and SPID, the difference being significant at several times of evaluation for PID, and on Day 2 for SPID evaluation in the PP (p = 0.01) and ITT analysis (p = 0.007).	acetylsalicylic acid lysinate	0-3	metastasis associated 1 family member 2	Homo sapiens	87-90
10835327-4	2000	A limited analysis of liquid from cystic fibrosis transmembrane conductance regulator (CFTR) knockout mice revealed no significant differences compared with littermate controls; however, Pseudomonas aeruginosa infection led to an increase in the salt concentration of ASL in cftr(+/+) mice.	acetylsalicylic acid lysinate	268-271	cystic fibrosis transmembrane conductance regulator	Mus musculus	87-91
9150326-9	1997	It is concluded that administration of lysine acetylsalicylate by inhalation protects the asthmatic airways against bradykinin-induced bronchoconstriction, thus suggesting that endogenous prostaglandins may play a contributory role in the bronchoconstriction to kinins in human asthma.	acetylsalicylic acid lysinate	39-62	kininogen 1	Homo sapiens	116-126
10436863-16	1999	LTC4S is profoundly overexpressed in the aspirin-induced asthmatic phenotype and correlates with overproduction of cysteinyl LTs and bronchial hyperreactivity to lysine aspirin.	acetylsalicylic acid lysinate	162-176	leukotriene C4 synthase	Homo sapiens	0-5
9150326-0	1997	Activity of inhaled lysine acetylsalicylate (L-ASA) on bradykinin-induced bronchoconstriction in asthmatics: evidence of contribution of prostaglandins.	acetylsalicylic acid lysinate	20-43	kininogen 1	Homo sapiens	55-65
8804929-0	1996	Changes in neurokinin A airway responsiveness with inhaled lysine-acetylsalicylate in asthma.	acetylsalicylic acid lysinate	59-82	tachykinin precursor 1	Homo sapiens	11-23
9150326-0	1997	Activity of inhaled lysine acetylsalicylate (L-ASA) on bradykinin-induced bronchoconstriction in asthmatics: evidence of contribution of prostaglandins.	acetylsalicylic acid lysinate	45-50	kininogen 1	Homo sapiens	55-65
9150326-3	1997	The aim of the present study was to investigate the effect of the potent cyclo-oxygenase inhibitor, lysine acetylsalicylate (L-ASA), administered by inhalation, on bradykinin-induced bronchoconstriction in a group of 12 asthmatic subjects.	acetylsalicylic acid lysinate	100-123	kininogen 1	Homo sapiens	164-174
9150326-3	1997	The aim of the present study was to investigate the effect of the potent cyclo-oxygenase inhibitor, lysine acetylsalicylate (L-ASA), administered by inhalation, on bradykinin-induced bronchoconstriction in a group of 12 asthmatic subjects.	acetylsalicylic acid lysinate	125-130	kininogen 1	Homo sapiens	164-174
9150326-7	1997	When compared to placebo, inhaled L-ASA reduced the airway responsiveness to bradykinin in 11 of the 12 subjects studied, the geometric mean (range) values for PC20 bradykinin increasing significantly (p<0.001) by 1.7 doubling dose from 0.55 (0.11-5.05) to 1.72 (0.26-6.05) mg x mL(-1) after placebo and L-ASA, respectively.	acetylsalicylic acid lysinate	34-39	kininogen 1	Homo sapiens	77-87
9150326-7	1997	When compared to placebo, inhaled L-ASA reduced the airway responsiveness to bradykinin in 11 of the 12 subjects studied, the geometric mean (range) values for PC20 bradykinin increasing significantly (p<0.001) by 1.7 doubling dose from 0.55 (0.11-5.05) to 1.72 (0.26-6.05) mg x mL(-1) after placebo and L-ASA, respectively.	acetylsalicylic acid lysinate	34-39	kininogen 1	Homo sapiens	165-175
8804929-3	1996	In this randomized, double-blind, placebo-controlled study, we have investigated the effect of the potent cyclooxygenase inhibitor, lysine acetylsalicylate (L-ASA) administered by inhalation, on the bronchoconstrictor response both to neurokinin A (NKA) and methacholine in nine asthmatic subjects.	acetylsalicylic acid lysinate	132-155	tachykinin precursor 1	Homo sapiens	235-247
8804929-3	1996	In this randomized, double-blind, placebo-controlled study, we have investigated the effect of the potent cyclooxygenase inhibitor, lysine acetylsalicylate (L-ASA) administered by inhalation, on the bronchoconstrictor response both to neurokinin A (NKA) and methacholine in nine asthmatic subjects.	acetylsalicylic acid lysinate	132-155	tachykinin precursor 1	Homo sapiens	249-252
8804929-7	1996	When compared with placebo, inhaled L-ASA reduced the airway responsiveness to NKA in 8 of the 9 subjects studied, the geometric mean (range) values for PC20 NKA increasing significantly from 153.2 (52.0-258.9) to 303.1 (83.4-668.5) micrograms.mL-1 after placebo and L-ASA, respectively.	acetylsalicylic acid lysinate	36-41	tachykinin precursor 1	Homo sapiens	79-82
8804929-7	1996	When compared with placebo, inhaled L-ASA reduced the airway responsiveness to NKA in 8 of the 9 subjects studied, the geometric mean (range) values for PC20 NKA increasing significantly from 153.2 (52.0-258.9) to 303.1 (83.4-668.5) micrograms.mL-1 after placebo and L-ASA, respectively.	acetylsalicylic acid lysinate	36-41	tachykinin precursor 1	Homo sapiens	158-161
8804929-9	1996	The small decrease in airway responsiveness to neurokinin A after administration of lysine acetylsalicylate by inhalation suggests that endogenous prostaglandins may play a contributory protective role in the airway response to neurokinin A in human asthma.	acetylsalicylic acid lysinate	84-107	tachykinin precursor 1	Homo sapiens	47-59
1476810-4	1992	IL-2 inhibited the migration of ASL into collagen gel and had no influence on the motility of ASL, but enhanced the expression of CD 26 antigen.	acetylsalicylic acid lysinate	32-35	interleukin 2	Homo sapiens	0-4
8451426-6	1993	The PPS significantly reduced blood loss in both the control pigs and those treated with venopirin (P < .05); thrombin coating was a statistically significant factor only in the venopirin-treated pigs.	acetylsalicylic acid lysinate	181-190	coagulation factor II, thrombin	Sus scrofa	113-121
8864252-8	1996	After adjustment for age, C4bp levels increased significantly with increasing ASL and ASA.	acetylsalicylic acid lysinate	78-81	complement component 4 binding protein alpha	Homo sapiens	26-30
8658372-7	1996	RESULTS: A decrease in both absolute mast cell numbers staining with mast cell tryptase (AA1) and the percentage of mast cells co-immunostaining with 5-lipoxygenase was seen in the ASA patients after lysine aspirin challenge compared with the non-ASA control group.	acetylsalicylic acid lysinate	200-214	AA1	Homo sapiens	89-92
8658372-7	1996	RESULTS: A decrease in both absolute mast cell numbers staining with mast cell tryptase (AA1) and the percentage of mast cells co-immunostaining with 5-lipoxygenase was seen in the ASA patients after lysine aspirin challenge compared with the non-ASA control group.	acetylsalicylic acid lysinate	200-214	arachidonate 5-lipoxygenase	Homo sapiens	150-164
1476810-6	1992	To make ASL therapy more effective to malignant glioma, the following measures should be recommended; 1) inject adequate volume of IL-2 into tumor cavity, 2) reduce the frequency of ASL administration, 3) wash out of glioma secreting factors, degenerated ASL and glioma cells in addition to reduce the volume of tumor tissue.	acetylsalicylic acid lysinate	8-11	interleukin 2	Homo sapiens	131-135
2680959-6	1989	Intravenous injection of aspirin DL-lysine (18 mg/kg) 30 minutes later markedly suppressed prostaglandin E2 and renin levels at all sites and clearly lowered arterial blood pressure (mean: from 120 +/- 6 to 110 +/- 5 mm Hg, p less than 0.01).	acetylsalicylic acid lysinate	25-42	renin	Homo sapiens	112-117
1930860-6	1991	In unilateral RVH, ASP suppressed renin release from the stenotic kidney and reduced the renal vein PRA ratio to less than 1.5 via the inhibition of PG synthesis, which is accelerated in that kidney.	acetylsalicylic acid lysinate	19-22	renin	Homo sapiens	34-39
2518282-4	1989	The protective effect of IL-1 + TNF against lethal pulmonary O2 toxicity could be partially inhibited by pre-injection of lysine acetylsalicylate or, less effectively, of ibuprofen.	acetylsalicylic acid lysinate	122-145	tumor necrosis factor	Rattus norvegicus	32-35
2906299-2	1988	In our studies, infusion of lysine acetylsalicylate (72 mg/min) increased basal insulin levels and amplified insulin responses to glucose (5 g i.v.	acetylsalicylic acid lysinate	28-51	insulin	Homo sapiens	80-87
2906299-2	1988	In our studies, infusion of lysine acetylsalicylate (72 mg/min) increased basal insulin levels and amplified insulin responses to glucose (5 g i.v.	acetylsalicylic acid lysinate	28-51	insulin	Homo sapiens	109-116
2880743-0	1986	The effect of lysine acetylsalicylate on somatostatin inhibition of insulin secretion induced by arginine.	acetylsalicylic acid lysinate	14-37	insulin	Homo sapiens	68-75
2880743-3	1986	Aim of this study is to determine the inhibitory effect of SRIF on insulin secretion induced by arginine after the administration of lysine acetylsalicylate (LAS) in a dose which inhibits the endogenous synthesis of prostaglandins.	acetylsalicylic acid lysinate	133-156	insulin	Homo sapiens	67-74
2880743-3	1986	Aim of this study is to determine the inhibitory effect of SRIF on insulin secretion induced by arginine after the administration of lysine acetylsalicylate (LAS) in a dose which inhibits the endogenous synthesis of prostaglandins.	acetylsalicylic acid lysinate	158-161	insulin	Homo sapiens	67-74
6419621-3	1983	Infusion of lysine acetylsalicylate to block the synthesis of endogenous PGE increased by twofold total insulin response to glucose and also converted insulin release to a multiphasic pattern.	acetylsalicylic acid lysinate	12-35	insulin	Homo sapiens	104-111
3936737-1	1985	Interactions between naloxone, phentolamine and lysine acetylsalicylate upon glucose induced insulin release.	acetylsalicylic acid lysinate	48-71	insulin	Homo sapiens	93-100
3936737-5	1985	In diabetics, acute insulin responses to glucose were significantly increased by all the agents tested (naloxone, phentolamine and lysine acetylsalicylate), but only the cyclooxygenase inhibitor significantly augmented second phase insulin secretion and glucose disappearance rates.	acetylsalicylic acid lysinate	131-154	insulin	Homo sapiens	20-27
6419621-3	1983	Infusion of lysine acetylsalicylate to block the synthesis of endogenous PGE increased by twofold total insulin response to glucose and also converted insulin release to a multiphasic pattern.	acetylsalicylic acid lysinate	12-35	insulin	Homo sapiens	151-158
6419621-4	1983	The infusion of exogenous PGE1 (0.2 microgram X kg-1 X min-1) or PGE2 (10 micrograms/min) in addition to lysine acetylsalicylate restored the typical biphasic pattern of insulin release and also decreased total insulin release to values similar to those of control studies.	acetylsalicylic acid lysinate	105-128	insulin	Homo sapiens	170-177
665123-1	1978	The effect of acute parenteral and chronic oral administration of lysine-acetylsalicylate and phenylbutazone on fasting and meal-stimulated serum gastrin levels was investigated in healthy volunteers.	acetylsalicylic acid lysinate	66-89	gastrin	Homo sapiens	146-153
6819169-1	1982	This study was designed to evaluate the influence of intravenous infusion (72 mg min-1) of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin synthesis, on glucose homeostasis in normal man.	acetylsalicylic acid lysinate	91-114	CD59 molecule (CD59 blood group)	Homo sapiens	81-86
6819169-1	1982	This study was designed to evaluate the influence of intravenous infusion (72 mg min-1) of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin synthesis, on glucose homeostasis in normal man.	acetylsalicylic acid lysinate	116-119	CD59 molecule (CD59 blood group)	Homo sapiens	81-86
6819169-5	1982	Plasma insulin rose twofold in response to LAS, while plasma glucagon remained unchanged.	acetylsalicylic acid lysinate	43-46	insulin	Homo sapiens	7-14
6796445-5	1981	Infusion of lysine acetylsalicylate (LAS), an inhibitor of endogenous PG synthesis, completely reversed the inhibitory effect of colchicine upon insulin secretion and also augmented acute insulin response to glucose (response before colchicine + LAS = 45 +/- 8 microunits/ml; response after colchicine + LAS = 51 +/- 9 microunits/ml, P less than 0.05).	acetylsalicylic acid lysinate	12-35	insulin	Homo sapiens	145-152
6796445-5	1981	Infusion of lysine acetylsalicylate (LAS), an inhibitor of endogenous PG synthesis, completely reversed the inhibitory effect of colchicine upon insulin secretion and also augmented acute insulin response to glucose (response before colchicine + LAS = 45 +/- 8 microunits/ml; response after colchicine + LAS = 51 +/- 9 microunits/ml, P less than 0.05).	acetylsalicylic acid lysinate	37-40	insulin	Homo sapiens	145-152
6784135-4	1981	In search of possible endogenous factors which impair insulin release, we have investigated the effect of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin (PGs) synthesis, upon insulin responses to glucose and arginine in subjects with type II (adult-on-set) diabetes mellitus.	acetylsalicylic acid lysinate	106-129	insulin	Homo sapiens	200-207
6784135-4	1981	In search of possible endogenous factors which impair insulin release, we have investigated the effect of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin (PGs) synthesis, upon insulin responses to glucose and arginine in subjects with type II (adult-on-set) diabetes mellitus.	acetylsalicylic acid lysinate	131-134	insulin	Homo sapiens	200-207
6784135-5	1981	Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01).	acetylsalicylic acid lysinate	72-75	insulin	Homo sapiens	6-13
6784135-5	1981	Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01).	acetylsalicylic acid lysinate	72-75	insulin	Homo sapiens	161-168
6784135-5	1981	Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01).	acetylsalicylic acid lysinate	93-96	insulin	Homo sapiens	6-13
6784135-5	1981	Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01).	acetylsalicylic acid lysinate	93-96	insulin	Homo sapiens	6-13
6784135-5	1981	Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01).	acetylsalicylic acid lysinate	93-96	insulin	Homo sapiens	6-13
6784135-5	1981	Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01).	acetylsalicylic acid lysinate	93-96	insulin	Homo sapiens	6-13
6784135-7	1981	Acute insulin response to arginine (5 g iv) was also increased by LAS infusion.	acetylsalicylic acid lysinate	66-69	insulin	Homo sapiens	6-13
467810-6	1979	Infusion of lysine acetylsalicylate (LAS), an inhibitor of endogenous PGE synthesis, completely reversed the inhibitory effect of furosemide on insulin secretion and also augmented acute insulin response to glucose (response before furosemide + LAS: 41 +/- 6 muU/ml; during furosemide + LAS: 50 +/- 7 muU/ml, N = 10, P less than 0.02).	acetylsalicylic acid lysinate	12-35	insulin	Homo sapiens	144-151
467810-6	1979	Infusion of lysine acetylsalicylate (LAS), an inhibitor of endogenous PGE synthesis, completely reversed the inhibitory effect of furosemide on insulin secretion and also augmented acute insulin response to glucose (response before furosemide + LAS: 41 +/- 6 muU/ml; during furosemide + LAS: 50 +/- 7 muU/ml, N = 10, P less than 0.02).	acetylsalicylic acid lysinate	37-40	insulin	Homo sapiens	144-151
848248-0	1977	Effect of lysine-acetylsalicylate on serum gastrin levels.	acetylsalicylic acid lysinate	10-33	gastrin	Mus musculus	43-50
32130033-9	2020	In CFTR-/- airways the serous acini, collecting ducts, and ciliated ducts fail to transport ions after forskolin stimulation, resulting in the production of smaller volumes of ASL with normal Cl-, Na+ and K+ concentration.	acetylsalicylic acid lysinate	176-179	CF transmembrane conductance regulator	Sus scrofa	3-7
33540496-12	2021	IL-7 levels reflected a feedback response to ASL, with a higher DeltaIL-7 in patients with ASL and a lower DeltaIL-7 in those without ASL (0.48 pg/mL vs. -0.66 pg/mL, p < 0.001).	acetylsalicylic acid lysinate	45-48	interleukin 7	Homo sapiens	0-4
33540496-12	2021	IL-7 levels reflected a feedback response to ASL, with a higher DeltaIL-7 in patients with ASL and a lower DeltaIL-7 in those without ASL (0.48 pg/mL vs. -0.66 pg/mL, p < 0.001).	acetylsalicylic acid lysinate	91-94	interleukin 7	Homo sapiens	0-4
30089726-13	2018	CONCLUSIONS: Our results suggest that CFTR-independent mechanisms increase ASL pH in people with CF.	acetylsalicylic acid lysinate	75-78	CF transmembrane conductance regulator	Homo sapiens	38-42
30664709-5	2019	Challenges of AERD-like Ptges-/- mice with inhaled lysine aspirin (Lys-ASA) elicit LTC4 synthesis and cause rapid intrapulmonary recruitment of platelets with adherent granulocytes, along with platelet- and CysLT2R-mediated increases in lung IL-33, IL-5, IL-13, and bronchoalveolar lavage fluid HMGB1.	acetylsalicylic acid lysinate	51-65	cysteinyl leukotriene receptor 2	Mus musculus	207-214
30664709-5	2019	Challenges of AERD-like Ptges-/- mice with inhaled lysine aspirin (Lys-ASA) elicit LTC4 synthesis and cause rapid intrapulmonary recruitment of platelets with adherent granulocytes, along with platelet- and CysLT2R-mediated increases in lung IL-33, IL-5, IL-13, and bronchoalveolar lavage fluid HMGB1.	acetylsalicylic acid lysinate	51-65	interleukin 33	Mus musculus	242-247
30664709-5	2019	Challenges of AERD-like Ptges-/- mice with inhaled lysine aspirin (Lys-ASA) elicit LTC4 synthesis and cause rapid intrapulmonary recruitment of platelets with adherent granulocytes, along with platelet- and CysLT2R-mediated increases in lung IL-33, IL-5, IL-13, and bronchoalveolar lavage fluid HMGB1.	acetylsalicylic acid lysinate	51-65	interleukin 5	Mus musculus	249-253
30664709-5	2019	Challenges of AERD-like Ptges-/- mice with inhaled lysine aspirin (Lys-ASA) elicit LTC4 synthesis and cause rapid intrapulmonary recruitment of platelets with adherent granulocytes, along with platelet- and CysLT2R-mediated increases in lung IL-33, IL-5, IL-13, and bronchoalveolar lavage fluid HMGB1.	acetylsalicylic acid lysinate	51-65	interleukin 13	Mus musculus	255-260
30664709-5	2019	Challenges of AERD-like Ptges-/- mice with inhaled lysine aspirin (Lys-ASA) elicit LTC4 synthesis and cause rapid intrapulmonary recruitment of platelets with adherent granulocytes, along with platelet- and CysLT2R-mediated increases in lung IL-33, IL-5, IL-13, and bronchoalveolar lavage fluid HMGB1.	acetylsalicylic acid lysinate	51-65	high mobility group box 1	Mus musculus	295-300
26528246-8	2015	Cystic fibrosis transmembrane conductance regulator (CFTR) plays a pivotal role in regulating the periciliary ASL.	acetylsalicylic acid lysinate	110-113	CF transmembrane conductance regulator	Homo sapiens	0-51
26342029-6	2015	Challenges of dust mite-primed ptges(-/-) mice with lysine aspirin induce IL-33-dependent MC activation and bronchoconstriction.	acetylsalicylic acid lysinate	52-66	interleukin 33	Mus musculus	74-79
29259090-9	2017	Together, these findings suggest that SLC6A14 activity plays a role in the modification of the initial stages of airway infection by altering the level of l-arginine in the ASL, which in turn affects the attachment of P. aeruginosaIMPORTANCE CF patients with shared CFTR gene mutations show significant variability in their clinical presentation of infectious lung disease.	acetylsalicylic acid lysinate	173-176	solute carrier family 6 member 14	Homo sapiens	38-45
29259090-9	2017	Together, these findings suggest that SLC6A14 activity plays a role in the modification of the initial stages of airway infection by altering the level of l-arginine in the ASL, which in turn affects the attachment of P. aeruginosaIMPORTANCE CF patients with shared CFTR gene mutations show significant variability in their clinical presentation of infectious lung disease.	acetylsalicylic acid lysinate	173-176	CF transmembrane conductance regulator	Homo sapiens	266-270
27497299-4	2016	NSUN3 specifically recognises the anticodon stem loop (ASL) of the tRNA, explaining why a mutation that compromises ASL basepairing leads to disease.	acetylsalicylic acid lysinate	55-58	NOP2/Sun RNA methyltransferase 3	Homo sapiens	0-5
26528246-8	2015	Cystic fibrosis transmembrane conductance regulator (CFTR) plays a pivotal role in regulating the periciliary ASL.	acetylsalicylic acid lysinate	110-113	CF transmembrane conductance regulator	Homo sapiens	53-57